神经妥乐平联合前列地尔治疗糖尿病周围神经病临床研究  

Clinical effect of neurotropin and lipo PGE1 on diabetic peripheral neuropathy

作　　者：田志强[1] 姜炎[1] 孙乐羽[1] 苗勤[1] 刘玉府[1] 

机构地区：[1]郑州大学第五附属医院神经内科第二病区,郑州450052

出　　处：《中国实用神经疾病杂志》2011年第16期10-12,共3页Chinese Journal of Practical Nervous Diseases

摘　　要：目的探讨神经妥乐平联合前列地尔治疗糖尿病周围神经病变的疗效。方法对74例糖尿病周围神经病患者分治疗组38例和照组36例。2组入院后均1次/d静滴前列地尔针20μg,治疗组1次/d静滴神经妥乐平针剂7.2 U,共3周。观察2组的观察治疗前后临床症状及神经传导速度。结果给予神经妥乐平联合前列地尔治疗组临床症状(总有效率89.5%,P<0.05)、神经传导速度改善明显好于单用前列地尔(P<0.01)。结论神经妥乐平联合前列地尔治疗可以有效改善临床症状及神经传导速度进而改善预后。Objective To observe the clinical effect of the neurotropin and lipo PGE1 on diabetic peripheral neuropathy. Methods Total 74 patients with DPN were randomly divided into treatment group of 38 cases and corntrol group of 36 cases. The control group was treated with lipo PGEI solved in NS 100 mL by intravenous drip once a day for 21 days; The treatment group was similar to the control group except neurotropin 7.2 U by intravenous drip once a day. Before and after treatment, the clinical symptoms and nerve conduction velocity were measured. Results The symptoms in both groups were significantly improved,but the total effective rate in treatment group was significantly better than that in control group （89.5% vs. 69.4%, P〈0.05）. And nerve conduction velocity after treatment was more higher than before treatment （P〉0.01）. Conclusion Neu- rotropin and lipo PGE1 can improve the clinical symptoms, nerve＇s conduction velocity, and clinical prognosis on diabetic pe- ripheral neuropathy.

关 键 词：神经妥乐平 前列地尔 糖尿病周围神经病变 

分 类 号：R587.2[医药卫生—内分泌]